A Study of Bempedoic Acid in Combination With Ezetimibe and Either Rosuvastatin or Atorvastatin in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia

Study acronym: TRICONOS
StatusActive, Not Recruiting
PhaseNot specified
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Enrollment closed, study ongoing Show 4 more changesShow less
    • Eligibility criteria expanded, about 10 words
    • Secondary endpoints: details revised at 4 of 8 entries
    • Study description expanded, about 10 words
    • Site details revised at 163 of 163 sites
  2. Re-verified, no change to tracked fieldsv20
  3. Site details revised at 1 of 163 sitesv19
  4. Site details revised at 8 of 163 sitesv18
  5. Site details revised at 9 of 163 sitesv17
  6. Site details revised at 4 of 163 sitesv16
  7. Trial sites expanded: 159 → 163 locationsv15
  8. Study sites: 152 to 159v14
  9. Study sites: 99 to 152v13
  10. Study sites: 65 to 99v12
  11. Study sites: 43 to 65v11
  12. Study sites: 31 to 43v10
  13. Study sites: 21 to 31v9
  14. Study sites: 8 to 21v8
  15. Study sites: 4 to 8v7
  16. Study sites: 1 to 4v6
  17. Primary completion date: Feb 1, 2027 to Jul 31, 2027
    • Study completion date: Feb 1, 2027 to Jan 31, 2028
    v5
  18. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Mar 3, 2025 to Feb 12, 2025
    v4
  19. Primary endpoint revised
    • Secondary endpoints revised (8)
    v3
  20. Re-verified, no change to tracked fieldsv2
  21. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Data on the real-world use and effectiveness and safety of bempedoic acid combined with both a statin and ezetimibe in clinical practice is limited. There is an increased focus on using combination therapy to lower LDL-C.
Trial Details
NCT Number NCT06686615
Lead Sponsor Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
Conditions
(from sponsor)		 Primary Hypercholesterolemiia, Mixed Dyslipidemia
Enrollment 2,000 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov